ESR1 and breast carcinoma: Compared to estrogen-receptor positive (ER+) and human epidermal growth factor amplified (HER2+) breast cancers, TNBCs have a rapid peak rate of recurrence as metastatic disease, often within 3–5 years of initial diagnosis [2].